• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例胰岛素瘤伴低血糖患者，使用兰瑞肽治疗比奥曲肽效果更佳。

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide.

作者信息

Yamaoka Keiko, Nagashima Shuichi, Okada Nobukazu, Sawayama Nagisa, Saito Shinsuke, Takahashi Manabu, Okada Kenta, Endo Kazuhiro, Koizumi Masaru, Sasanuma Hideki, Ebihara Ken, Kasajima Atsuko, Fukushima Noriyoshi, Sata Naohiro, Ishibashi Shun

机构信息

Division of Endocrinology and Metabolism Department of Medicine Jichi Medical University Shimotsuke Japan.

Department of Surgery Jichi Medical University Shimotsuke Japan.

出版信息

Clin Case Rep. 2021 May 19;9(5):e04118. doi: 10.1002/ccr3.4118. eCollection 2021 May.

DOI:10.1002/ccr3.4118
PMID:34026158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8133073/
Abstract

Long-acting somatostatin analogs, including lanreotide slow release (LAN-SR) and octreotide long-acting release (OCT-LAR), can improve hypoglycemia in insulinoma. LAN-SR may be more beneficial in some patients with insulinoma than OCT-LAR.

摘要

长效生长抑素类似物，包括缓释兰瑞肽（LAN-SR）和长效奥曲肽（OCT-LAR），可改善胰岛素瘤患者的低血糖症状。在某些胰岛素瘤患者中，LAN-SR可能比OCT-LAR更有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/202f/8133073/0b81dc11ed11/CCR3-9-e04118-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/202f/8133073/0b81dc11ed11/CCR3-9-e04118-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/202f/8133073/0b81dc11ed11/CCR3-9-e04118-g002.jpg

相似文献

1
A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide.一例胰岛素瘤伴低血糖患者，使用兰瑞肽治疗比奥曲肽效果更佳。
Clin Case Rep. 2021 May 19;9(5):e04118. doi: 10.1002/ccr3.4118. eCollection 2021 May.
2
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.对临床上可用于治疗肢端肥大症的生长抑素类似物制剂的批判性分析。
J Clin Endocrinol Metab. 2008 Aug;93(8):2957-68. doi: 10.1210/jc.2008-0027. Epub 2008 May 13.
3
Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.长效生长抑素类似物治疗肢端肥大症的荟萃分析。
J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73. doi: 10.1210/jc.2005-0260. Epub 2005 May 10.
4
[Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].奥曲肽长效释放制剂与兰瑞肽缓释制剂治疗中国活动性肢端肥大症术后患者的成本效益分析
Zhonghua Yi Xue Za Zhi. 2017 Mar 14;97(10):765-769. doi: 10.3760/cma.j.issn.0376-2491.2017.10.010.
5
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.长效兰瑞肽和奥曲肽长效注射剂对既往未经治疗的肢端肥大症患者肿瘤缩小及生长激素分泌过多的长期影响。
Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71. doi: 10.1046/j.0300-0664.2001.01438.x.
6
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.醋酸奥曲肽长效注射剂与兰瑞肽缓释剂治疗肢端肥大症患者的比较。
Clin Endocrinol (Oxf). 2000 Nov;53(5):577-86. doi: 10.1046/j.1365-2265.2000.01134.x.
7
PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.PRESTO 2：一项国际调查，评估神经内分泌肿瘤或肢端肥大症患者使用长效生长抑素类似物最新设备/配方的注射体验。
Adv Ther. 2023 Feb;40(2):671-690. doi: 10.1007/s12325-022-02360-6. Epub 2022 Dec 11.
8
Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.长效兰瑞肽和长效奥曲肽治疗肢端肥大症时对胆囊运动的不同影响。
Eur J Endocrinol. 1999 Dec;141(6):590-4. doi: 10.1530/eje.0.1410590.
9
Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.长效奥曲肽LAR与缓释兰瑞肽治疗肢端肥大症的比较。
Pituitary. 2000 Oct;3(2):61-5. doi: 10.1023/a:1009997506216.
10
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.长效奥曲肽（LAR）：其在肢端肥大症治疗中的应用综述
Drugs. 2003;63(22):2473-99. doi: 10.2165/00003495-200363220-00014.

本文引用的文献

1
Pasireotide for malignant insulinoma.帕西瑞肽用于治疗恶性胰岛素瘤。
Hormones (Athens). 2016 Apr;15(2):271-276. doi: 10.14310/horm.2002.1639.
2
Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour.一名患有恶性多分泌性胰腺神经内分泌肿瘤的患者在长效奥曲肽剂量增加后出现了危及生命的持续性低血糖症。
Endocrinol Diabetes Metab Case Rep. 2015;2015:140097. doi: 10.1530/EDM-14-0097. Epub 2015 Jan 1.
3
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.
兰瑞肽长效凝胶与卡麦角林联合生物疗法治疗与多发性内分泌腺瘤病1型相关的胰岛素瘤
Endocrine. 2014 Aug;46(3):678-81. doi: 10.1007/s12020-013-0145-2. Epub 2014 Jan 3.
4
Effective therapy of insulinoma by using long-acting somatostatin analogue. A case report and literature review.使用长效生长抑素类似物有效治疗胰岛素瘤。病例报告及文献综述。
Exp Clin Endocrinol Diabetes. 2012 Feb;120(2):68-72. doi: 10.1055/s-0031-1287792. Epub 2011 Dec 20.
5
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.综述文章：生长抑素类似物治疗胃肠胰神经内分泌（类癌）肿瘤。
Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88. doi: 10.1111/j.1365-2036.2009.04174.x. Epub 2009 Oct 21.
6
Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.成人低血糖症的评估与管理：内分泌学会临床实践指南
J Clin Endocrinol Metab. 2009 Mar;94(3):709-28. doi: 10.1210/jc.2008-1410. Epub 2008 Dec 16.
7
A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.一项关于长效兰瑞肽（Lanreotide Autogel）和长效可重复注射奥曲肽对肢端肥大症患者生长激素（GH）和胰岛素样生长因子-1（IGF-1）影响的为期12个月的随机交叉研究。
Clin Endocrinol (Oxf). 2008 Mar;68(3):473-80. doi: 10.1111/j.1365-2265.2007.03067.x. Epub 2007 Oct 17.
8
Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma.泼尼松对难治性转移性胰腺胰岛素瘤低血糖的症状控制
Support Care Cancer. 2005 Sep;13(9):760-2. doi: 10.1007/s00520-005-0840-5. Epub 2005 Jun 16.
9
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles.长效奥曲肽和缓释兰瑞肽制剂具有不同的药代动力学特征。
J Clin Pharmacol. 2005 Jul;45(7):836-44. doi: 10.1177/0091270005277936.
10
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.奥曲肽治疗胰岛素瘤患者：对低血糖的疗效、与奥曲肽扫描闪烁显像的关系以及抗sst2A和抗sst5抗体免疫染色情况
Eur J Endocrinol. 2005 May;152(5):757-67. doi: 10.1530/eje.1.01901.